Krystal Biotech (KRYS) Net Income towards Common Stockholders Growth (1y) (2017 - 2026)
Krystal Biotech (KRYS) Net Income towards Common Stockholders Growth (1y) (2017 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Net Income Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
-88.68% |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
-58.11% |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
104.24% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
-129.68% |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
-290.15% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
-230.18% |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
59.59% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Krystal Biotech |
10.23 Bn |
9.41 Bn |
110.03 Mn |
56.53% |
| Date | Value |
|---|
| Mar 31, 2026 |
56.53% |
| Dec 31, 2025 |
12.93% |
| Sep 30, 2025 |
192.00% |
| Jun 30, 2025 |
146.50% |
| Mar 31, 2025 |
3,734.01% |
| Dec 31, 2024 |
423.62% |
| Sep 30, 2024 |
-66.34% |
| Jun 30, 2024 |
146.88% |
| Mar 31, 2024 |
102.06% |
| Dec 31, 2023 |
127.12% |
| Sep 30, 2023 |
370.51% |
| Jun 30, 2023 |
-18.15% |
| Mar 31, 2023 |
9.34% |
| Dec 31, 2022 |
-46.99% |
| Sep 30, 2022 |
-91.48% |
| Jun 30, 2022 |
-71.78% |
| Mar 31, 2022 |
-215.99% |
| Dec 31, 2021 |
-110.02% |
| Sep 30, 2021 |
-62.22% |
| Jun 30, 2021 |
-139.47% |
